2022 Drug Pricing Packaging 
European Pharmaceutical Review
JUNE 24, 2022
2022 is probably the biggest year in EU pharmaceutical law that I have seen in 30 years. 2022 is undeniably a critical year for change in the pharmaceutical industry: for the first time in several decades, the European Union (EU)’s pharmaceutical legislation is up for review. Key areas of potential legislative change. Future outlook.
Pharmaceutical Technology
NOVEMBER 21, 2022
in 2022 to JPY9.498 trillion ($68.08 One reason at play is the concern that the Japanese pharmaceutical industry has shown about the impact of annual price revisions. This trend continues as it estimated that the FY2022 price revision led to an average price reduction of 4% to 5% for major drug makers.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Safe Biologics
DECEMBER 6, 2023
REMINDER: FDA Draft Guidance Would Remove Interchangeability Statement from Interchangeable Biosimilars Comments Due November 17th On September 15th, the Food and Drug Administration (FDA) released draft guidance removing the interchangeability statement from the product label/package insert. ASBM surveys of U.S. However, S.6
Pharmaceutical Technology
MARCH 10, 2023
Consequentially, the five-year average price trend in Lebanon for all medicines has increased to 1,123%. GlobalData reviews the key events leading up to these current price trends in Lebanon. Branded medicines accounted for roughly 76% of the Lebanese market in 2022, according to GlobalData’s Price Intelligence (POLI) database.
Pharmaceutical Technology
NOVEMBER 21, 2022
in 2022 to JPY9.498 trillion ($68.08 One reason at play is the concern that the Japanese pharmaceutical industry has shown about the impact of annual price revisions. This trend continues as it estimated that the FY2022 price revision led to an average price reduction of 4% to 5% for major drug makers.
Proxsys Rx
APRIL 19, 2024
Two potential 340B developments for 2024 In an article dated January 5, the subscriber-only website 340B Report projected that “In 2024, congressional gridlock and election year dynamics will likely slow momentum on any comprehensive 340B program reform package.”
Proxsys Rx
JANUARY 12, 2024
Two potential 340B developments for 2024 In an article dated January 5, the subscriber-only website 340B Report projected that “In 2024, congressional gridlock and election year dynamics will likely slow momentum on any comprehensive 340B program reform package.”
Expert insights. Personalized for you.
105 
Let's personalize your content